Alumis IncNASDAQ:ALMS
- LAST PRICE11.1600
- TODAY'S CHANGE (%)-0.8100 (-6.7669%)
- Bid / Lots4.9000/ 1
- Ask / Lots12.8500/ 1
- Open / Previous Close12.1300 / 11.9700
- Day Range
- 52 Week Range
- Volume170,719
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALMS |
|---|---|---|
| 09:32 ET | 839 | 12.2278 |
| 09:34 ET | 200 | 12.18 |
| 09:36 ET | 1600 | 12.01 |
| 09:38 ET | 579 | 11.97 |
| 09:39 ET | 125 | 11.92 |
| 09:41 ET | 200 | 11.81 |
| 09:43 ET | 1334 | 11.6 |
| 09:45 ET | 600 | 11.975 |
| 09:48 ET | 100 | 11.9 |
| 09:50 ET | 300 | 11.87 |
| 10:03 ET | 900 | 11.75 |
| 10:10 ET | 100 | 11.75 |
| 10:12 ET | 906 | 11.855 |
| 10:14 ET | 1000 | 11.82 |
| 10:19 ET | 600 | 11.825 |
| 10:21 ET | 100 | 11.75 |
| 10:28 ET | 100 | 11.7 |
| 10:30 ET | 100 | 11.73 |
| 10:33 ET | 450 | 11.715 |
| 10:35 ET | 332 | 11.62 |
| 10:37 ET | 13504 | 11.285 |
| 10:39 ET | 1567 | 11.37 |
| 10:44 ET | 800 | 11.33 |
| 10:48 ET | 100 | 11.4 |
| 10:50 ET | 100 | 11.4 |
| 10:51 ET | 272 | 11.34 |
| 10:57 ET | 200 | 11.34 |
| 11:02 ET | 100 | 11.34 |
| 11:04 ET | 100 | 11.34 |
| 11:06 ET | 239 | 11.34 |
| 11:08 ET | 301 | 11.395 |
| 11:18 ET | 100 | 11.44 |
| 11:22 ET | 700 | 11.4 |
| 11:26 ET | 100 | 11.465 |
| 11:29 ET | 100 | 11.4 |
| 11:31 ET | 500 | 11.39 |
| 11:36 ET | 300 | 11.395 |
| 11:51 ET | 500 | 11.3583 |
| 11:54 ET | 1000 | 11.3 |
| 11:56 ET | 3360 | 11.08 |
| 11:58 ET | 319 | 11.2 |
| 12:09 ET | 100 | 11.269719 |
| 12:12 ET | 100 | 11.2 |
| 12:20 ET | 500 | 11.19 |
| 12:25 ET | 100 | 11.19 |
| 12:27 ET | 168 | 11.14 |
| 12:32 ET | 133 | 11.168 |
| 12:36 ET | 600 | 11.1 |
| 12:59 ET | 800 | 11.13 |
| 01:01 ET | 200 | 11.12 |
| 01:14 ET | 529 | 11.09 |
| 01:15 ET | 4588 | 11 |
| 01:17 ET | 300 | 11.015 |
| 01:24 ET | 1300 | 11.08 |
| 01:26 ET | 100 | 11.08 |
| 01:30 ET | 100 | 11.08 |
| 01:35 ET | 7200 | 11.035 |
| 01:37 ET | 700 | 11.035 |
| 01:39 ET | 2704 | 11.045 |
| 01:42 ET | 300 | 11.045 |
| 01:46 ET | 200 | 11 |
| 01:48 ET | 400 | 11.03 |
| 01:55 ET | 200 | 11.04 |
| 01:57 ET | 1050 | 10.96 |
| 02:02 ET | 800 | 10.95 |
| 02:06 ET | 1000 | 10.9954 |
| 02:08 ET | 200 | 10.975 |
| 02:09 ET | 200 | 10.95 |
| 02:11 ET | 100 | 10.96 |
| 02:13 ET | 100 | 10.94 |
| 02:15 ET | 800 | 11.02 |
| 02:31 ET | 300 | 11.03 |
| 02:33 ET | 100 | 11.02 |
| 02:45 ET | 100 | 10.9974 |
| 02:47 ET | 100 | 10.99 |
| 02:49 ET | 100 | 10.995 |
| 02:54 ET | 700 | 10.96 |
| 02:56 ET | 684 | 11.005 |
| 02:58 ET | 100 | 11.02 |
| 03:09 ET | 27267 | 10.95 |
| 03:12 ET | 580 | 11 |
| 03:14 ET | 200 | 10.97 |
| 03:16 ET | 1800 | 11.005 |
| 03:18 ET | 400 | 10.995 |
| 03:20 ET | 400 | 10.97 |
| 03:21 ET | 700 | 10.93 |
| 03:23 ET | 860 | 10.95 |
| 03:27 ET | 200 | 10.91 |
| 03:32 ET | 1586 | 10.88 |
| 03:34 ET | 900 | 10.92 |
| 03:36 ET | 100 | 10.915 |
| 03:38 ET | 100 | 10.93 |
| 03:39 ET | 100 | 10.915 |
| 03:41 ET | 700 | 10.93 |
| 03:45 ET | 2800 | 10.965 |
| 03:48 ET | 2395 | 10.89 |
| 03:50 ET | 2253 | 10.88 |
| 03:52 ET | 2030 | 10.89 |
| 03:54 ET | 1388 | 10.92 |
| 03:56 ET | 200 | 10.92 |
| 03:57 ET | 643 | 10.925 |
| 03:59 ET | 20285 | 11.16 |
Sep 27, 2024
Sep 3, 2024
Alumis to Participate in Upcoming September Investor Conferences, from 4:29PM ET on Tuesday Sep 03, 2024 by Dow Jones
4:29PM ET on Tuesday Sep 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alumis Inc | 600.9M | -3.1x | --- |
LENZ Therapeutics Inc | 601.1M | -2.5x | --- |
Oculis Holding AG | 501.8M | -5.8x | --- |
Mineralys Therapeutics Inc | 584.8M | -4.4x | --- |
Allogene Therapeutics Inc | 619.0M | -1.8x | --- |
Lexicon Pharmaceuticals Inc | 614.5M | -2.1x | --- |
Company Information
Alumis Inc. is a clinical-stage biopharmaceutical company. It develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. It has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.
Contact Information
- Headquarters
- 280 East Grand AvenueSOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-231-6625
- Fax
- 302-531-3150
Executives
- Chairman of the Board, President, Chief Executive Officer
- Martin Babler
- Chief Financial Officer
- John Schroer
- Senior Vice President - People and Culture
- Derrick Richardson
- Chief Scientific Officer
- David Goldstein
- General Counsel, Corporate Secretary
- Sara Klein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $600.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 51.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.65 |
Book Value | $0.70 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
